Granules India Q2 FY27 Revenue Crosses ₹1500 Cr, PAT Up 39% YoY
Granules India's Q2 FY27 revenue crossed ₹1500 crore (₹15,600 million), up 20% YoY. PAT surged 39% YoY to ₹1,818 million. The company achieved a net cash position of ₹828 crore. It continues to focus on complex generics and peptide CDMO, with two potential first-to-file ANDAs filed in H1 FY27.
The announcement details significant financial performance improvements (revenue and profit growth), a strong net cash position, and positive regulatory updates (USFDA audit), which are material to investors.
The company reported strong year-on-year growth in revenue and profit, achieved a net cash position, and successfully navigated a USFDA audit, indicating positive operational and financial performance.
Granules India Limited announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company reported a significant milestone with quarterly revenue crossing ₹1500 crore (₹15,600 million), marking a 20% year-on-year growth. EBITDA stood at ₹338 crore (₹3,376 million), up 21% year-on-year, despite higher input and logistics costs due to tensions in West Asia.
The company's Profit After Tax (PAT) saw a substantial increase of 39% year-on-year, reaching ₹1,818 million. Gross margin was reported at 64.4%, a decrease of 134 basis points year-on-year, attributed to elevated input costs. Granules India continues to focus on complex generics and peptide CDMO, filing two potential first-to-file ANDAs in the first half of the fiscal year, bringing the total to three.
The company ended the quarter with a net cash position of ₹828 crore (₹8,280 million) after receiving the balance warrant proceeds, which will be invested in R&D, manufacturing, and quality initiatives. Granules India also successfully concluded a USFDA audit at its Gagillapur site, with constructive progress and a belief that observations can be fully addressed through corrective actions.
Geographically, North America contributed 72% of the revenue with 14% year-on-year growth, while Europe showed strong growth of 65% year-on-year. The company's R&D efforts remain a strategic priority, with 159 dossiers filed globally and 103 approvals. Granules India is committed to sustainability, aiming for Net Zero by 2050 and achieving significant renewable electricity usage.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.